BridgeBio Pharma Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

BridgeBio Pharma Stock Summary

BridgeBio Pharma competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people.

BridgeBio Pharma Key Financial Ratios

BridgeBio Pharma Key Balance Sheet Accounts

BridgeBio Pharma Key Income Statement Accounts

BridgeBio Pharma Key Cash Accounts

BridgeBio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining BridgeBio Pharma's current stock value. Our valuation model uses many indicators to compare BridgeBio Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BridgeBio Pharma competition to find correlations between indicators driving BridgeBio Pharma's intrinsic value. More Info.BridgeBio Pharma is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, BridgeBio Pharma's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BridgeBio Pharma's earnings, one of the primary drivers of an investment's value.

BridgeBio Pharma Systematic Risk

Today, most investors in BridgeBio Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BridgeBio Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BridgeBio Pharma growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of BridgeBio Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BridgeBio Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of BridgeBio Pharma based on widely used predictive technical indicators. In general, we focus on analyzing BridgeBio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BridgeBio Pharma's daily price indicators and compare them against related drivers.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.